<DOC>
	<DOCNO>NCT01014845</DOCNO>
	<brief_summary>The primary purpose study determine whether preventive hepatitis E effective prevention hepatitis E occur least 30 day administration third dose vaccine . The secondary purpose study evaluate safety immunogenicity immunopersistence study vaccine . The initial study plan end month 19 result analyse used registration purpose . The extended study continue assess long-term efficacy , immunogenicity safety .</brief_summary>
	<brief_title>Clinical Trial Recombinant Hepatitis E Vaccine</brief_title>
	<detailed_description>Participants randomly allocate two group , one receive Hepatitis E vaccine receive hepatitis B vaccine . The study carry two stage . In first stage ( phase 3a ) , 2 645 subject enrol actively monitor solicited adverse event 1 month injection . Serum sample subject collect day 0 , 7m , 13m , 19m timely evaluate immunogenicity immuno-persistency . In second stage ( phase 3b ) , another 109 959 subject enrol monitor solicited adverse event 1 month injection . Serum sample 9764 subject among phase 3b participant collect day 0 , 7m , 19m timely evaluate immunogenicity immuno-persistency . Serious adverse event trial follow . Suspected hepatitis case identify establish active hepatitis surveillance system . The sentinels system comprise healthcare facility field . Suspected hepatitis define patient present systemic symptom fatigue and/or loss appetite 3 day alanine aminotransferase ( ALT ) exceed 2.5 fold upper limit normal range ( ULN ) . Paired serum obtain patient time presentation 2-6 week later . Sera test HEV antibody HEV-RNA .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis E</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy people age 16 year 65 year old time first vaccination , normal intelligence agree sign inform consent form . Subjects reside study region next 19 month . Free history hepatitis B hepatitis E. Can comply request study . Axillary temperature 37 degree centigrade . For dose 1 : Having vaccine immunoglobulin within two week ; Having allergic history vaccine medicine Eclampsia , epilepsy , encephalopathy history mental disease family ; Thrombocytopenia disturbance blood coagulation would lead muscle injection taboo ; Fixed suspect deficiency immunologic function , contain immunosuppressant treatment ( radiation therapy , chemical treatment , steroid hormone , antimetabolite , cytotoxic drug ) , genetic defect ( e.g . fabism ) , HIV factor ; congenital malformation , eccyliosis severe chronic disease ( e.g . Down Syndrome , diabetes , sickle cell anemia mental disease ) ; fix suspect disease include fever , active infection , liver kidney disease , angiocardiopathy , malignancy , acute chronic disease ; join clinical study undergoing ; woman pregnant lactation . For dose 2 3 : Severe allergy dose 1 2 ; Severe adverse reaction associate last vaccination ; New occurrence symptom meet dose 1 exclusion criterion first dose .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>hepatitis E</keyword>
	<keyword>vaccine</keyword>
	<keyword>efficacy</keyword>
</DOC>